Compare Charles River Laboratories Intl. Inc (CRL) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Impinj Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.25 (market cap $13.46B), while Impinj Inc trades at $179.47 (market cap $5.32B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.5× Impinj Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Impinj Inc nearer its low. Which is the better fit depends on your goals.
| CRL | PI | |
|---|---|---|
Market Cap | $13.46B | $5.32B |
Sector | Health | Technology |
52-Week High | $282.00 | $241.91 |
52-Week Low | $145.57 | $91.34 |
Enterprise Value | $16.30B | $5.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Impinj (PI) trades at $177.33, up 0.61% with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported record Q2 2026 revenue and earnings beats, though profitability remains negative with -7.26% net margins. Recent news highlights institutional accumulation and positive earnings momentum despite insider selling activity.
The stock offers growth potential from RFID market leadership and strong quarterly performance, but faces risks from negative profitability, high valuation multiples, and concentrated revenue streams. Analyst consensus remains strongly bullish with a $186 price target, representing 4.9% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
